Mikhail L. Gordeev

Mikhail L. Gordeev

Auto-generated profile, based on publicly available information

Mikhail L. Gordeev

Almazov National Medical Research Centre

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2021 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
IKIvan A. Kozyrev
Ivan A. Kozyrev
NKNikolai A. Kotin
Nikolai A. Kotin
IAIgor I. Averkin
Igor I. Averkin
AIAndrey A. Ivanov
Andrey A. Ivanov
ALAlexander A. Latypov
Alexander A. Latypov
EGEvgeny V. Grekhov
Evgeny V. Grekhov

26 November 2019 in Russian Journal of Cardiology
Verified
Journal Article
Open access
OIOlga Irtyuga
Olga Irtyuga
VCV. I. Chistyakova
V. I. Chistyakova
ATA. O. Tenchurina
A. O. Tenchurina
VSV. N. Solntsev
V. N. Solntsev
EKE. A. Kushnareva
E. A. Kushnareva
EDElena Demchenko
Elena Demchenko

3 May 2020 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
VZV. V. Zaitsev
V. V. Zaitsev
Alexandr GurschenkovAlexandr Gurschenkov
Alexandr Gurschenkov
LMLubov Borisovna Mitrofanova
Lubov Borisovna Mitrofanova
ARA. V. Ryzhkov
A. V. Ryzhkov
EKE. E. Kazakova
E. E. Kazakova
OMOlga Moiseeva
Olga Moiseeva
Objective To evaluate prospects for clinical use of circulating biomarkers for characterizing fibrotic changes in the myocardium of patients with hypertrophic cardiomyopathy (HCMP) with left ventricular (LV) outflow tract obstruction. Materials and Methods This was a prospective study with a 12-month follow-up period. The study included 47 patients (29 females and 18 males) with obstructive HCMP who were selected for septal reduction. Echocardiography (EchoCG), cardiac magnetic resonance imaging (MRI) and measurements of serum C-reactive protein, N-terminal pro-brain natriuretic peptide, and relevant circulating markers of fibrosis (TGF-β1, MMP-2,-9, TIMP-1, galectin-3, sST2, CITP, PICP, and PIIINP) were performed for all patients. All patients were evaluated at baseline and at 7 days, 6 and 12 months following surgical treatment. Morphometrical analysis of intraoperative biopsy samples was performed for evaluation of the degree of fibrotic changes. Patients received beta-blockers (95.7%), angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (34%), loop diuretics (68.1%), aldosterone antagonists (34%), and statins (66%). Results Women with HCMP were older and more frequently had additional risk factors (arterial hypertension). Men had a higher risk of sudden cardiac death. Histological study of intraoperative myocardial biopsy samples showed that the area of fibrotic changes was 13.9±6.9%. According to cardiac MRI mean area of delayed contrast enhancement was 8.7±3.3% of LV myocardial mass. No association was established between traditional cardiovascular risk factors and severity of myocardial fibrotic changes or levels of circulating fibrosis markers. Perhaps that was due to the modifying effect of the drug therapy received by HCMP patients. According to EchoCG maximum pressure gradient in the LV outflow tract before the surgical treatment was 88 (55; 192) mm Hg, and interventricular septal thickness was 22 (16; 32) mm. A considerable decrease (p=0.0002) in the LV outflow tract gradient was observed after myectomy in all patients. At the same time, the left ventricular dimension, which tended to decrease in the early postoperative period, returned to baseline values by the 6th month of follow-up. Conclusion The study confirmed the increase in relevant circulating markers of fibrosis in patients with obstructive HCMP. At the same time, no correlation was observed between levels of circulating biomarkers and severity of fibrosis according to data of histology and cardiac MRI, which was probably due to the modifying effect of drug therapy and limited sampling.

27 January 2024 in Annals of Critical Care
Verified
Journal Article
Open access
PDF file
ABAndrei Evgen'evich Bautin
Andrei Evgen'evich Bautin
AMAleksandr Marichev
Aleksandr Marichev
LKL. I. Karpova
L. I. Karpova
ARAleksey Radovskiy
Aleksey Radovskiy
EBE. K. Barygin
E. K. Barygin
MGM. L. Gordeev
M. L. Gordeev
INTRODUCTION: Plasma cell-free hemoglobin (Hbf) has a negative effect on the results of cardiac surgery. OBJECTIVE: Analysis of the dynamics of the Hbf during cardiosurgical operations with CPB. Identification of the main factors for increasing the Hbf. MATERIALS AND METHODS: A prospective, single-center, cohort study included 50 patients who underwent cardiac surgery with CPB. Hbf was monitored before surgery, during CPB (10 minutes after the start, then every 30 minutes) and every 6 hours for two days. RESULTS: An increase in Hbf levels was found in 90 % of surgical procedure. In 8 % of cases, hemolysis was mild (0.1 < Hbf ≤ 0.4 g/l), in 48 % — moderate (0.4 < Hbf < 1 g/l), severe (Hbf ≥ 1 g/l) was after 34 % of operations. After weaning from CPB Hbf rapidly decreases and after 12 hours drop to the preoperative level. Aortic cross-clamping is a risk factor with an odds ratio of 1.038 (p = 0.036). A positive correlation was established between the Hbf level and the duration of CPB (r = 0.76; p < 0.001). In ROC-analysis, a good predictive ability for development of severe hemolysis was demonstrated by the time of CPB: AUC 0.74 (p = 0.014) with a threshold value of 76 minutes. During CABG, severe hemolysis developed significantly less frequently than during valve corrections — 12.5 % versus 44.1 %, p = 0.026. Hbf content was significantly lower with an initial hemoglobin concentration < 140 g/l than in patients with an initial hemoglobin level ≥ 140 g/l — 0.7 (0.5; 0.95) g/l versus 0.9 (0.7; 1.28) g/l, p = 0.036. CONCLUSIONS: Hemolysis is typical for the cardiac surgeries with CPB. The time of aoral clamping and CPB, the type of surgcry, the hemoglobin content before surgcry have an impact on the severity of hemolysis.

19 January 2021 in Kardiologiia
Verified
Journal Article
Closed access
PDF file
MSMaria Simonenko
Maria Simonenko
PFPetr Fedotov
Petr Fedotov
YSYu. V. Sazonova
Yu. V. Sazonova
KMK. I. Monosova
K. I. Monosova
MSM. Yu. Sitnikova
M. Yu. Sitnikova
MKM. A. Karpenko
M. A. Karpenko
Aim      This study presents the experience of managing patients with COVID-19 after cardiac transplantation (CT). Material and methods  Infectious complications (IC) following CT are a leading cause for morbidity and mortality. A prolonged incubation period, atypical IC symptoms, and originally altered results of laboratory and instrumental diagnosis are characteristic of recipients due to immunosuppression. In 2020, the coronavirus infection (COVID-19) rapidly spread worldwide, and timely diagnosis and searching for effective treatments for this disease became a major challenge. From January 2010 through July 2020, 148 patients received orthotopic heart transplants at the V.A. Almazov National Medical Research Center; 34 of these patients died by the present time and were excluded from this analysis. 114 patients were included into the retrospective evaluation of results. These patients had been a part of the group followed up at the Center for more than a month. Results From March through July 2020, 12 (10.5 %) of 114 CT recipients were infected with the virus SARS-CoV-2. In 75 % (n=9) of the sick patients, the COVID-19 infection developed after more than one year after CT. From the first day of clinical symptoms, mycophenolic acid/everolimus were temporarily suspended. The outpatient treatment was started on the first day and included an antiviral therapy (oseltamivir), mucolytics (bromhexine), vitamin C, and anticoagulants. If the disease onset was associated with pyretic fever the empiric antibacterial levofloxacin treatment was administered due to a high risk of mixed infection. Hospitalized patients with moderately severe COVID-19 (n=3) were treated with oxygen inhalation through nasal cannula and prone position with a positive effect. Conclusion      Remote counseling of patients after CT and consistency of the outpatient treatment with recommendations of managing transplant physicians provided timely diagnosis of IC, early administration of treatment, and the absence of COVID-19 complications. Reducing the regimen of immunosuppressive therapy (antiproliferative agents) for up to 14 days facilitated infection control and was not associated with acute rejection crisis and/or impairment of the transplant function.

1 July 2018 in Transplantation
Verified
Journal Article
Closed access
MSMaria Simonenko
Maria Simonenko
PFPetr Fedotov
Petr Fedotov
YSYulia Sazonova
Yulia Sazonova
NGNatalia Gussaova
Natalia Gussaova
VRVadim Rubinchik
Vadim Rubinchik
MKMikhail Karpenko
Mikhail Karpenko
Purpose To estimate the impact and the frequency of development thyroid disorders (TD) after heart transplantation (HT). Methods From 2010 to 2016 we performed 80 HT (mean age 46,0±14,0 yrs). Before HT 33% (n=26) of patients had TD: autoimmune thyroiditis - 42,3% (n=11), amiodarone-induced thyrotoxicosis type 1 (Graves' disease) - 3,8% (n=1), amiodarone-induced thyrotoxicosis (AIT) type 2 – 38,5% (n=10), diffuse nodular goiter - 11,5% (n=3) and thyroid adenoma - 3,8% (n=1). Before HT the level of thyroid stimulating hormone (TSH) in all recipients was normal or matched to subclinical hypothyroidism (SCH) (2,209±1,251 mMe/l vs. 7,115±4,533 mMe/l, p<0,05). Before HT 1 patient underwent hemithyroidectomy due to thyroid adenoma. All recipients were treated with triple-drug therapy (steroids, calcineurin inhibitors, mycophenolate mofetil) and induction (basiliximab – 76% (n=61), thymoglobulin – 24% (n=19)). Every 6 months the level of TSH was controlled or more frequent in case of pretransplantation thyroid history. If TSH was not in normal values, other thyroid hormones were measured and ultrasound investigation performed. Results After HT TD developed in 7,4% (n=4) patients without previous thyroiditis history: 1 - hypothyroidism, 3 - post-transplanted thyrotoxicosis (PTT). During 1st yr after HT PTT was diagnosed in 6,3% (n=5) recipients who were successfully treated by thiamazole or/and prednisone (TSH - 0,008 [0,003;0,163] mMe/l vs. 3,327 [1,539;3,836] mMe/l). Moreover, 2 of them had TD history: 1- autoimmune thyroiditis, 1 – AIT type 2. In long-term follow-up there was no evidence of PTT. During 1st yr hypothyroidism was found in 10% (n=8) patients and then were treated with levothyroxine therapy (TSH – 8,006 [5,681;23,640] mMe/l vs. 1,963 [1,882;2,482] mMe/l). After HT in 10 from 17 recipients (58,8%) with hypothyroidism and in 3 from 9 (33,3%) – with euthyroidism the level of TSH increased. In 2 months after HT significant hypothyroidism manifested in 1 recipient: TSH increased (59,922 mMe/l), free thyroxine (T4) decreased (5,2 pmol/l). In 5 yrs after HT AIT type 2 was diagnosed in 3 other patients. In long-term follow-up induction did not impact on the level of TSH. We found correlation between time spent on mechanical ventilatory support (MVS) and PTT (r=0,8; p30%). After HT imbalance of thyroid status was found in 15 from 26 recipients (57,7%) with TD history and in 4 from 54 (7,4%) – without it. The absolute risk of TD deterioration or development was 36,6% in TD group vs. 6,9% - the onset of TD (p<0,001). Conclusion Thyroid status deteriorated in majority of heart transplanted patients. After HT level of TSH needs to be under control in all recipients, especially in those with thyroid disease history. Anti-thyroid medications are successfull.